Cambria Pharmaceuticals Inc.

Although only a small percentage of ALS cases seem tied to the mutant form of SOD1, the deep knowledge about it provides Cambria Pharmaceuticals with a platform for assaying compounds it intends to develop against ALS and other neurodegenerative diseases.